Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors
(ST) and hematological malignancies. We summarized the CD47-related clinical research …

The identification of thrombospondin-1 as an angiogenesis inhibitor in 1990 prompted
interest in its role in cancer biology and potential as a therapeutic target. Decreased …

Immunotherapy using PD-1 and CTLA4 inhibitors to stimulate T cell immunity has achieved
significant clinical success. However, only a portion of patients benefit from T cell-based …

Cancer immunotherapy has revolutionized the paradigm for the clinical management of
cancer. While FDA-approved cancer immunotherapies thus far mainly exploit the adaptive …

Blockade of CD47, the “do not eat me” signal, has limited effects in solid tumors despite its
potent antitumor effects in hematopoietic malignancies. Taking advantage of the high …

Background The CD47‐signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …

Background Immunotherapy has emerged as a novel strategy for cancer treatment following
surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric …

Abstract Cluster of differentiation 47 (CD47) is a transmembrane protein that is ubiquitously
found on the surface of many cells in the body and uniquely overexpressed by both solid …

Unprecedented breakthroughs have been made in cancer immunotherapy in recent years.
Particularly immune checkpoint inhibitors have fostered hope for patients with cancer …

The transmembrane protein, CD47, is recognized as an important innate immune
checkpoint, and CD47-targeted drugs have been in development with the aim of inhibiting …